Pulmonary hypertension in interstitial lung disease: Clinical trial design and endpoints: A consensus statement from the Pulmonary Vascular Research Institute's Innovative Drug Development Initiative—Group 3 Pulmonary Hypertension

Pulmonary hypertension (PH) associated with interstitial lung disease (ILD) is an attractive target for clinical trials of PH medications. There are many factors that need to be considered to prime such studies for success. The patient phenotype most likely to respond to the intervention requires we...

Descripción completa

Detalles Bibliográficos
Autores principales: Nathan, Steven D., Fernandes, Peter, Psotka, Mitchell, Vitulo, Patrizio, Piccari, Lucilla, Antoniou, Katerina, Nikkho, Sylvia M., Stockbridge, Norman
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Review Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9780699/
https://www.ncbi.nlm.nih.gov/pubmed/36578976
http://dx.doi.org/10.1002/pul2.12178

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9780699/
https://www.ncbi.nlm.nih.gov/pubmed/36578976
http://dx.doi.org/10.1002/pul2.12178

Ejemplares similares